Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.60 USD
-0.70 (-30.43%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.53 -0.07 (-4.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 1 - 20 ( 73 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fadraciclib Shows Efficacy Against CDKN2A, CDKN2B, MTAP Deletion Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Delivery of Encouraging Clinical Results Defies Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Positive Phase 1 Solid Tumor/Lymphoma Data with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Takeaways Regarding Fadraciclib And CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 Oral Fadraciclib Data Shows Favorable Safety And Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Positive Early Solid Tumor/ Lymphoma Data with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Early Solid Tumor/Lymphoma Results with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J